LUNG Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -46.13% compared to Pulmonx Corp.'s net margin of 14.61%. Pulmonx Corp.'s return on equity of -77.88% beat Electromed, Inc.'s return on equity of 20.35%.

Pulmonx Corp. has a consensus price target of $5.17, signalling upside risk potential of 288.47%. On the other hand Electromed, Inc. has an analysts' consensus of $37.00 which suggests that it could grow by 58.87%. Given that Pulmonx Corp. has higher upside potential than Electromed, Inc., analysts believe Pulmonx Corp. is more attractive than Electromed, Inc..

Pulmonx Corp. has a beta of 0.187, which suggesting that the stock is 81.276% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.317, suggesting its less volatile than the S&P 500 by 68.266%.

Pulmonx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx Corp. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Pulmonx Corp. quarterly revenues are $22.6M, which are larger than Electromed, Inc. quarterly revenues of $18.9M. Pulmonx Corp.'s net income of -$10.4M is lower than Electromed, Inc.'s net income of $2.8M. Notably, Pulmonx Corp.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 22.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx Corp. is 0.62x versus 2.91x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Escalon Medical Corp. has a net margin of -46.13% compared to Pulmonx Corp.'s net margin of 2.72%. Pulmonx Corp.'s return on equity of -77.88% beat Escalon Medical Corp.'s return on equity of -12.94%.

Pulmonx Corp. has a consensus price target of $5.17, signalling upside risk potential of 288.47%. On the other hand Escalon Medical Corp. has an analysts' consensus of -- which suggests that it could grow by 7641.94%. Given that Escalon Medical Corp. has higher upside potential than Pulmonx Corp., analysts believe Escalon Medical Corp. is more attractive than Pulmonx Corp..

Pulmonx Corp. has a beta of 0.187, which suggesting that the stock is 81.276% less volatile than S&P 500. In comparison Escalon Medical Corp. has a beta of 0.181, suggesting its less volatile than the S&P 500 by 81.879%.

Pulmonx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Escalon Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx Corp. pays -- of its earnings as a dividend. Escalon Medical Corp. pays out -- of its earnings as a dividend.

Pulmonx Corp. quarterly revenues are $22.6M, which are larger than Escalon Medical Corp. quarterly revenues of $3.6M. Pulmonx Corp.'s net income of -$10.4M is lower than Escalon Medical Corp.'s net income of $97.7K. Notably, Pulmonx Corp.'s price-to-earnings ratio is -- while Escalon Medical Corp.'s PE ratio is 154.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx Corp. is 0.62x versus 0.15x for Escalon Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Guided Therapeutics, Inc. has a net margin of -46.13% compared to Pulmonx Corp.'s net margin of -1236.67%. Pulmonx Corp.'s return on equity of -77.88% beat Guided Therapeutics, Inc.'s return on equity of --.

Pulmonx Corp. has a consensus price target of $5.17, signalling upside risk potential of 288.47%. On the other hand Guided Therapeutics, Inc. has an analysts' consensus of -- which suggests that it could grow by 46666566.67%. Given that Guided Therapeutics, Inc. has higher upside potential than Pulmonx Corp., analysts believe Guided Therapeutics, Inc. is more attractive than Pulmonx Corp..

Pulmonx Corp. has a beta of 0.187, which suggesting that the stock is 81.276% less volatile than S&P 500. In comparison Guided Therapeutics, Inc. has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.34%.

Pulmonx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guided Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx Corp. pays -- of its earnings as a dividend. Guided Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pulmonx Corp. quarterly revenues are $22.6M, which are larger than Guided Therapeutics, Inc. quarterly revenues of $60K. Pulmonx Corp.'s net income of -$10.4M is lower than Guided Therapeutics, Inc.'s net income of -$742K. Notably, Pulmonx Corp.'s price-to-earnings ratio is -- while Guided Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx Corp. is 0.62x versus 24.64x for Guided Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX Corp. has a net margin of -46.13% compared to Pulmonx Corp.'s net margin of -1.25%. Pulmonx Corp.'s return on equity of -77.88% beat IRIDEX Corp.'s return on equity of -119.2%.

Pulmonx Corp. has a consensus price target of $5.17, signalling upside risk potential of 288.47%. On the other hand IRIDEX Corp. has an analysts' consensus of $2.75 which suggests that it could grow by 180.53%. Given that Pulmonx Corp. has higher upside potential than IRIDEX Corp., analysts believe Pulmonx Corp. is more attractive than IRIDEX Corp..

Pulmonx Corp. has a beta of 0.187, which suggesting that the stock is 81.276% less volatile than S&P 500. In comparison IRIDEX Corp. has a beta of 0.753, suggesting its less volatile than the S&P 500 by 24.713%.

Pulmonx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx Corp. pays -- of its earnings as a dividend. IRIDEX Corp. pays out -- of its earnings as a dividend.

Pulmonx Corp. quarterly revenues are $22.6M, which are larger than IRIDEX Corp. quarterly revenues of $14.7M. Pulmonx Corp.'s net income of -$10.4M is lower than IRIDEX Corp.'s net income of -$184K. Notably, Pulmonx Corp.'s price-to-earnings ratio is -- while IRIDEX Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx Corp. is 0.62x versus 0.32x for IRIDEX Corp.. Usually stocks with elevated PS ratios are considered overvalued.